The use of prophylaxis in 2663 children and adults with haemophilia: Results of the 2006 Canadian national haemophilia prophylaxis survey

Haemophilia

Volumn 14, Issue 5, 2008, Pages 923-930

  Biss, Tina T ^a,d   Chan, A K ^b   Blanchette, V S ^a,c   Iwenofu, L N ^c   Mclimont, M ^c   Carcao, Manuel D ^a,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^d ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Canada; Factor VIII IX inhibitor; Haemophilia A; Haemophilia B; Prophylaxis; Survey

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR 9 INHIBITOR; BLOOD CLOTTING INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BLEEDING TENDENCY; CANADA; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG INFUSION; FREQUENCY ANALYSIS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION; FACTOR IX; FACTOR VIII; HEALTH CARE SURVEYS; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HUMANS; ISOANTIBODIES; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 51249108178     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01810.x     Document Type: Article

References (25)

1. Ahlberg A. Haemophilia in Sweden VII. Incidence, treatment, and prophylaxis of arthropathy and other musculoskeletal manifestations of haemophilia A and B. Acta Orthopaediatr Scand 1965; 77: 3-132.
2. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years'experience of prophylactic treatment in severe haemophilia A and B. J Int Med 1992; 232: 25-32.
3. 5Fischer K, van der Bom JG, Molho P et al. Prophylactic versus on-demand strategies for severe haemophilia A: A comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-52.
4. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 603-5.
5. Bohn RL, Avorn J, Glynn RJ, Choodnovskiy I, Haschemeyer R, Aledort LM. Prophylactic use of factor VIII: An economic evaluation. Thromb Haemost 1998; 79: 932-7.
6. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.
7. Richards M, Altisent C, Batarova A et al. Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data Haemophilia 2007; 13: 473-9.
8. Goudemand J. Pharmaco-economic aspects of inhibitor treatment. Eur J Haematol 1998; 63(Suppl.): 24-7.
9. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: Consensus recommendations. Haemophilia 2007; 13(Suppl. 1): 1-22.
10. DiMichele DM, Kroner BL, The North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: Practices, outcomes, outcome predictors. J Thromb Haemost 2002; 87: 52-7.
11. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 2007; 13: 249-55.
12. Blanchette VS, McCready M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003; 9(Suppl. 1): 19-26.
13. World Health Organization. Report of Joint WHO/WFH Meeting on the Control of Haemophilia: Delivery of Treatment for Haemophilia, 2002. Available at: http://whqlibdoc.who.int/hq/2002/WHO_WFH_ISTH_WG_02.6.pdf.
14. Hoots WK, Nugent DJ. Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost 2006; 96: 433-40.
15. Kreuz W, Escuriola-ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? The German experience. Haemophilia 1998; 4: 413-7.
16. Fischer K, van der Bom JG, Mauser-Brunschoten P et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99: 2337-41.
17. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
18. van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
19. Brackmann HH, Eickhoff HJ, Oldenburg J, Hammerstein U. Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience. Haemostasis 1992; 22: 251-8.
20. Feldman BM, Pai M, Rivard GE et al. Tailored prophylaxis in severe hemophilia A: Interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36.
21. Hay CRM. Prophylaxis in adults with haemophilia. Haemophilia 2007; 13(Suppl. 2): 10-5.
22. Fischer K, van der Bom JG, Prejs R et al. Discontinuation of prophylactic therapy in severe haemophilia: Incidence and effects on outcome. Haemophilia 2001; 7: 544-50.
23. van Dijk K, Fischer K, van der Bom JG, Scheibel E, Ingerslev J, van den Berg HM. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005; 130: 107-12.
24. DiMichele DM, Hay CR. The international immune tolerance study: A multicenter prospective randomized trial in progress. J Thromb Haemost 2006; 4: 2271-3.
25. Gringeri A, Musso R, Mazzucconi MG et al. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007; 13: 373-9.